Vivos Therapeutics, Inc. - VVOS

SEC FilingsOur VVOS Tweets

About Gravity Analytica

Recent News

  • 07.21.2025 - Two nights of home polysomnography in healthy 7- 14-year-old children – Feasibility and intraindividual variability
  • 07.21.2025 - Use of the Complete Airway Repositioning and Expansion (CARE) approach in 220 patients with Obstructive Sleep Apnea (OSA): A retrospective cohort study
  • 07.21.2025 - Multicenter clinical trial for the treatment of obstructive sleep apnea with a non‑permanent orthodontic intraoral device in children
  • 07.21.2025 - Improved diagnostic accuracy for pediatric obstructive sleep apnea using an out-of-center sleep test
  • 07.16.2025 - What Is Moderate OSA?
  • 06.18.2025 - What Is Mild OSA?
  • 06.11.2025 - Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
  • 05.23.2025 - Common Treatment Options For OSA
  • 05.22.2025 - Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
  • 05.14.2025 - Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Recent Filings

  • 07.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 06.20.2025 - 3 Initial statement of beneficial ownership of securities
  • 06.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
  • 06.13.2025 - EX-99.1 EX-99.1
  • 06.13.2025 - 8-K Current report
  • 06.06.2025 - 8-K Current report
  • 05.23.2025 - 8-K Current report
  • 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
  • 05.15.2025 - EX-99.1 EX-99.1
  • 05.15.2025 - 8-K Current report